The TruSight Myeloid Sequencing Panel uses expert-defined content and proven next-generation sequencing (NGS) technology to identify somatic variants in myeloid malignancies.
The panel content was designed by a consortium of recognized experts in blood cancer disorders and targets genes frequently mutated in:
The TruSight Myeloid Sequencing Panel covers 15 full genes (exons only) and 39 additional genes where oncogenic hotspots are covered, providing a comprehensive assessment of the key genes known to be involved in myeloid malignancies in a single test. The result is an accurate, cost-effective solution that enables researchers to profile liquid tumors.
TruSight Myeloid libraries are ideally suited to run on a desktop sequencer and perform alignment and variant calling with the MiSeq Reporter or Local Run Manager Amplicon workflow with Somatic Variant Caller. Filtering and annotation can then be performed using BaseSpace Variant Interpreter.
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| MiniSeq System | Samples per run: mid output: 2-3, high output: 8 (based on 95% amplicons at > 500x coverage) | 2 × 150 bp (max recommended) |
| MiSeq System | 8 samples per run with v3 reagents (based on 95% amplicons at > 500x coverage) | 2 × 150 bp (max recommended) |
| NextSeq 550 System | Samples per run: mid output: 48, high output: 96 (based on 95% amplicons at > 500x coverage) | 2 × 150 bp (max recommended) |
| TruSight Myeloid Sequencing Panel | AmpliSeq for Illumina Myeloid Panel | AmpliSeq for Illumina Cancer Hotspot Panel v2 | |
|---|---|---|---|
| Assay Time | 8 hours | 5.5 – 7.5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) | 5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) |
| Cancer Type | Hematologic | Hematologic | Pan-Cancer, Solid Tumor |
| Content Specifications | Targets 54 genes associated with myeloid malignancies. Probes amplify 568 amplicons from tumor suppressor genes and mutational hotspots. | Targets biomarkers across 69 genes (40 key DNA target genes, 29 RNA fusion driver genes, and 5 gene expression levels) | Hotspot regions of 50 genes with known associations to cancer |
| Description | For somatic mutation detection studies in myeloid malignancies. | Targeted panel to study 40 DNA genes, 29 RNA fusion driver genes, and 5 gene expression levels associated with myeloid cancers. | Somatic analysis research into hotspot regions of 50 cancer-related genes. |
| Hands-On Time | 3 hours | < 1.5 hours | < 1.5 hours |
| Input Quantity | 50 ng | 20 ng high-quality DNA; 10 ng high-quality RNA (10 ng recommended per pool) |
1–100 ng (10 ng recommended per pool) |
| Method | Amplicon Sequencing, Targeted DNA Sequencing | Amplicon Sequencing, Targeted DNA Sequencing, Targeted RNA Sequencing | Amplicon Sequencing, Targeted DNA Sequencing |
| Multiplexing | Up to 96-plex | Up to 96-plex | 96 dual index combinations |
| Nucleic Acid Type | DNA | RNA, DNA | DNA |
| Specialized Sample Types | Not FFPE-Compatible | Blood, Bone Marrow, Not FFPE-Compatible | FFPE Tissue |
| Species Category | Human | Human | Human |
Next-generation sequencing has the potential to open new doors for detecting blood cancers.
Learn More| ABL1 | CEBPA | HRAS | MYD88 | SF3B1 |
| ASXL1 | CSF3R | IDH1 | NOTCH1 | SMC1A |
| ATRX | CUX1 | IDH2 | NPM1 | SMC3 |
| BCOR | DNMT3A | IKZF1 | NRAS | SRSF2 |
| BCORL1 | ETV6/TEL | JAK2 | PDGFRA | STAG2 |
| BRAF | EZH2 | JAK3 | PHF6 | TET2 |
| CALR | FBXW7 | KDM6A | PTEN | TP53 |
| CBL | FLT3 | KIT | PTPN11 | U2AF1 |
| CBLB | GATA1 | KRAS | RAD21 | WT1 |
| CBLC | GATA2 | MLL | RUNX1 | ZRSR2 |
| CDKN2A | GNAS | MPL | SETBP1 |
TruSight Myeloid Sequencing Panel
Data Sheet | PDF < 1 MB
TruSight Myeloid Sequencing Panel Support Documentation
Custom Protocol Selector
Generates customized, end-to-end instructions
These sequencing reagent kits offer increased stability and robustness over the v2 kit version.
Tailor panel designs for human disease research efficiently and conveniently by selecting from a catalog of over 5,000 pretested genes.
Targeted panel investigating the exonic regions of 409 genes with known associations to cancer.
Targeted custom research panels optimized for sequencing specific targets or genomic content of interest.
Targeted DNA and RNA research panel investigating variants across 161 genes associated with a range of cancer types.
Targeted research panel investigating somatic and germline variants in BRCA1 and BRCA2.
